noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Terminix Holdings LLC

International Women’s Day: How ServiceMaster Women Bring “Give to Gain”[...]
CenterPoint Energy Inc.

More than 99.8% of CenterPoint Energy customers experienced no impacts[...]
Lakeland Industries Inc.

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Lakeland Industries, Inc.[...]

Healthcare

Fibrobiologics Inc.

03/06/2026 | Press release | Distributed by Public on 03/06/2026 15:04

Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 4, 2026, the Compensation Committee of the Board of Directors of FibroBiologics, Inc. (the "Company") approved a new annual base salary of $400,000, effective January 1, 2026, for Jason D. Davis, the Company's Chief Financial Officer. Mr. Davis' target amount as a percentage of base salary for annual non-equity incentive compensation remains at 40%.

Fibrobiologics Inc. published this content on March 06, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 06, 2026 at 21:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]